Literature DB >> 6439178

Contribution of the receptor pathway to low density lipoprotein catabolism in humans. New methods for quantitation.

H R Slater, L McKinney, C J Packard, J Shepherd.   

Abstract

Receptor-mediated catabolism of low density lipoprotein (LDL) by cultured cells depends on the presence of functionally significant arginine and lysine residues on the lipoprotein apoprotein. When these are blocked, the recognition process is abolished, and catabolism of the modified lipoprotein is restricted to other mechanisms. Accurate discrimination between the activities of the receptor and nonreceptor pathways in vivo depends critically on the metabolic properties of this chemically modified lipoprotein. Here we report our experiences with two lysine-modified LDL tracers, glucosylated LDL (GLC-LDL) and 2-hydroxyacetaldehyde-treated LDL (HOET-LDL). The fractional clearance rate of GLC-LDL (0.25 +/- 0.05 pools/day, n = 5) was 50% of that of control material (0.51 +/- 0.09 pools/day) injected simultaneously into normal subjects. The HOET-LDL was also retarded in its clearance. Here, however, the fractional clearances of the control (0.37 +/- 0.06 pools/day, n = 6) and modified lipoprotein (0.19 +/- 0.03 pools/day) were lower than those obtained by the glucosylation procedure. We suspect that the prolonged incubation required for glucosylation of LDL artifactually accelerated its catabolism. The HOET-LDL does not suffer from this defect and seems to be a better tracer of the receptor-independent pathway. In a group of 10 subjects, HOET-LDL was metabolically indistinguishable from 1,2 cyclohexanedione-treated, arginine-modified LDL.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6439178     DOI: 10.1161/01.atv.4.6.604

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  3 in total

1.  Catabolic rate of low density lipoprotein is influenced by variation in the apolipoprotein B gene.

Authors:  T Demant; R S Houlston; M J Caslake; J J Series; J Shepherd; C J Packard; S E Humphries
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

2.  Effect of YM-53601, a novel squalene synthase inhibitor, on the clearance rate of plasma LDL and VLDL in hamsters.

Authors:  Tohru Ugawa; Hirotoshi Kakuta; Hiroshi Moritani; Osamu Inagaki
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

Review 3.  Cholesterol and Its Metabolites in Tumor Growth: Therapeutic Potential of Statins in Cancer Treatment.

Authors:  Adele Chimento; Ivan Casaburi; Paola Avena; Francesca Trotta; Arianna De Luca; Vittoria Rago; Vincenzo Pezzi; Rosa Sirianni
Journal:  Front Endocrinol (Lausanne)       Date:  2019-01-21       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.